U.S. Department of Health & Human Services

NLM Digital Collections

Search

Search Constraints

Start Over You searched for: Copyright Public domain Remove constraint Copyright: Public domain Subjects United States Remove constraint Subjects: United States Genre Technical Report Remove constraint Genre: Technical Report
Number of results to display per page

Search Results

21. An analysis of private-sector prices for hospital admissions

nlm:nlmuid-101703988-pdf

24. Medicaid managed care: improved oversight needed of payment rates for long-term services and supports : report to Congressional requesters

nlm:nlmuid-101704057-pdf

25. Foster care: HHS has taken steps to support states' oversight of psychotropic medications, but additional assistance could further collaboration : report to Congressional requesters

nlm:nlmuid-101704061-pdf

27. Defense civil support: DOD, HHS, and DHS should use existing coordination mechanisms to improve their pandemic preparedness : report to the Committee on Armed Services, House of Representatives

nlm:nlmuid-101704071-pdf

29. Drug-free community support program: agencies have strengthened collaboration but could enhance grantee compliance and performance monitoring : report to Congressional committees

nlm:nlmuid-101704075-pdf

31. Requirements for transactions with first responders under section 582 of the Federal Food, Drug, and Cosmetic Act--compliance policy

nlm:nlmuid-101704830-pdf

32. Providing regulatory submissions in electronic format--certain human pharmaceutical product applications and related submissions using the eCTD specifications

nlm:nlmuid-101704838-pdf

33. Projecting demand for the services of primary care doctors:

nlm:nlmuid-101708769-pdf

36. Out-of-pocket expenditures for adults with health care expenses for multiple chronic conditions, U.S. civilian noninstitutionalized population, 2014

nlm:nlmuid-101701118-pdf

37. Trends in enrollment, offers, eligibility and take-up for employer-sponsored insurance: private sector, by state Medicaid expansion status, 2008-2015

nlm:nlmuid-101701121-pdf

38. Emergency use authorization of medical products and related authorities: guidance for industry and other stakeholders

nlm:nlmuid-101712946-pdf

39. Form FDA 3674--certifications to accompany drug, biological product, and device applications/submissions: guidance for sponsors, industry, researchers, investigators, and food and drug administration staff

nlm:nlmuid-101712948-pdf

40. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs--questions and answers (R3)

nlm:nlmuid-101712951-pdf

42. IRB waiver or alteration of informed consent for clinical investigations involving no more than minimal risk to human subjects: guidance for sponsors, investigators, and institutional review boards

nlm:nlmuid-101713098-pdf

44. Federal subsidies for health insurance coverage for people under age 65: 2017 to 2027

nlm:nlmuid-101713191-pdf

46. Generic Drug User Fee Amendments of 2012: questions and answers related to self-identification of facilities, review of generic drug submissions, and inspections and compliance

nlm:nlmuid-101713196-pdf

47. Antibacterial therapies for patients with an unmet medical need for the treatment of serious bacterial diseases

nlm:nlmuid-101713206-pdf

49. Use of real-world evidence to support regulatory decision-making for medical devices: guidance for industry and Food and Drug Administration staff

nlm:nlmuid-101713224-pdf

51. Design considerations and pre-market submission recommendations for interoperable medical devices: guidance for industry and Food and Drug Administration staff

nlm:nlmuid-101713256-pdf

52. Evaluation and reporting of age-, race-, and ethnicity-specific data in medical device clinical studies: guidance for Industry and Food and Drug Administration staff

nlm:nlmuid-101713258-pdf

53. Establishing the performance characteristics of in vitro diagnostic devices for the detection or detection and differentiation of human papillomaviruses: guidance for Industry and Food and Drug Administration staff

nlm:nlmuid-101713268-pdf

54. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 1(R1) : residue on ignition/sulphated ash general chapter

nlm:nlmuid-101713272-pdf

55. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 2(R1) : test for extractable volume of parenteral preparations general chapter

nlm:nlmuid-101713277-pdf

56. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 3(R1) : test for particulate contamination : subvisible particles general chapter

nlm:nlmuid-101713281-pdf

57. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 4A(R1) : microbiological examination of nonsterile products : microbial enumeration tests general chapter

nlm:nlmuid-101713288-pdf

58. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 4B(R1) : microbiological examination of nonsterile products : tests for specified microorganisms general chapter

nlm:nlmuid-101713291-pdf

59. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 4C(R1) : microbiological examination of nonsterile products : acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use general chapter

nlm:nlmuid-101713296-pdf

60. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 5(R1) : disintegration test general chapter

nlm:nlmuid-101713299-pdf

61. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 9(R1) : tablet friability general chapter

nlm:nlmuid-101713302-pdf

62. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 10(R1) : polyacrylamide gel electrophoresis general chapter

nlm:nlmuid-101713306-pdf

63. Antibiotics: FDA has encouraged development, but needs to clarify the role of draft guidance and develop qualified infectious disease product guidance : report to Congressional requesters

nlm:nlmuid-101713330-pdf

64. Workplace safety and health: information on OSHA training for workers on workplace hazards : report to the Chairman, Subcommittee on Health, Employment, Labor, and Pensions, Committee on Education and the Workforce, House of Representatives

nlm:nlmuid-101713337-pdf

66. Antibiotic resistance: more information needed to oversee use of medically important drugs in food animals : report to Congressional requesters

nlm:nlmuid-101713360-pdf

68. Medicare provider education: oversight of efforts to reduce improper billing needs improvement : report to the Chairman, Committee on Finance, U.S. Senate

nlm:nlmuid-101713369-pdf

69. Medicaid program integrity: CMS should build on current oversight efforts by further enhancing collaboration with states : report to the Chairman, Committee on Finance, U.S. Senate

nlm:nlmuid-101713370-pdf

70. Pediatric trauma centers: availability, outcomes, and federal support related to pediatric trauma care : report to Congressional requesters

nlm:nlmuid-101713371-pdf

71. Veterans' health care: preliminary observations on veterans' access to choice program care : testimony before the Committee on Veterans' Affairs, House of Representatives

nlm:nlmuid-101713373-pdf

73. Veterans health administration: actions needed to better recruit and retain clinical and administrative staff : testimony before the Subcommittee on Health, Committee on Veterans' Affairs, House of Representatives

nlm:nlmuid-101713377-pdf

78. Medicaid personal care services: more harmonized program requirements and better data are needed : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

nlm:nlmuid-101713411-pdf

79. Emerging infectious diseases: actions needed to ensure improved response to Zika virus disease outbreaks : testimony before the Subcommittee on Oversight and Investigations, Committee on Energy and Commerce, House of Representatives

nlm:nlmuid-101713412-pdf

80. Veterans Affairs: improper payment estimates and ongoing efforts for reduction : testimony before the Subcommittee on Oversight and Investigations, Committee on Veterans' Affairs, House of Representatives

nlm:nlmuid-101713413-pdf

81. Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions: annex 8 (R1) : sterility test general chapter

nlm:nlmuid-101713430-pdf

82. Preliminary analysis of legislation that would replace subsidies for health care with block grants

nlm:nlmuid-101713545-pdf

84. Review of access and quality of care in SCHIP using standardized national performance measures

nlm:nlmuid-101322414-pdf

89. The aging services network: accomplishments and challenges in serving a growing elderly population

nlm:nlmuid-101490538-pdf